Research for treatments, prevention and a cure
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

Vaccines and Immunotherapies (VIT)

CTN 239: Phase II study of AGS-004 an immunotherapeutic agent in combination with ART followed by ART interruption

Trial results

Print Friendly, PDF & Email

A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption


CTN 239 aimed to assess the efficacy and safety of a personalized immunotherapy during a 12-week ART structured treatment interruption. This was a two-year, open label (where both the investigator and participant knew who is receiving the experimental drug) examination of the ability of AGS-004 to improve immune control of viral replication.

Study Design

Following screening and leukopheresis, participants received one injection of 0.6 ml AGS-004 every four weeks four times while continuing on ART. At week 12, participants with a viral load of less than 1000 copies/ml continued with AGS-004 and an ART interruption. At week 26, participants discussed with the study doctor, according to their viral load rebound, whether to continue with AGS-004 or restart ART alone.

The study agent, AGS-004, is created from a person’s own dendritic cells—white blood cells that stimulate the body’s immune system—and a sample of their HIV virus. This is the first experimental treatment designed from a person’s HIV genetic material and their body’s cells.


Forty-seven participants who were on their first antiretroviral drug regimen and had a CD4 cell count greater than or equal to 450 cells/mm3 for at least three months before study onset were recruited for the study.


Final analysis of this phase II study of an autologous dendritic cell immunotherapy (AGS-004) showed positive outcomes in primary endpoint of viral load control.


Researchers concluded that the experimental treatment resulted in an unexpectedly long delay in viral rebound, time to peak viral load during structured treatment interruption and a reduced viral load when compared to pre-ART levels.

Additional Information


Routy JP, Boulassel MR, Nicolette CA, Jacobson JM. Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy. J Med Virol. 2012;84(6):885-9.

Principal Investigator

Dr. Jean-Pierre Routy

Latest News

CTN at AIDS 2018

| Uncategorized | No Comments

The 22nd International AIDS Conference (AIDS 2018) is the premier gathering for individuals working in the field of HIV, policy makers,…

CTNPT 031 — The HAVARTI trial

| Uncategorized | No Comments

“Our study will test whether a licensed and commonly used medication could lead to a functional cure for HIV infection,”…

CTN at CAHR 2018

| Uncategorized | No Comments

Along with supporting CAHR as a Bronze Sponsor, the CTN is proud to host several important events throughout the week.

CTNPT 029: Group Therapy for People Living with HAND

| Uncategorized | No Comments

Approximately half of the aging HIV-positive population will be affected by HIV-Associated Neurocognitive Disorder (HAND). People with HAND can experience…

Research for treatments, prevention and a cure